Nanoform Finland Plc – Manager’s transactions – Goncalo Andrade
Nanoform Finland Plc – Manager’s transactions – September 2, 2020 at 03:00 p.m. Finnish time
Manager’s transaction related to Nanoform Finland Plc’s other senior manager Goncalo Andrade’s share subscription with stock options from option program 2/2019.
Nanoform Finland Plc – Managers’ Transactions
____________________________________________
Person subject to the notification requirement
Name: Goncalo Andrade
Position: Other senior manager
Issuer: Nanoform Finland Plc
LEI: 743700JJO2NU8LBS1592
Notification type: INITIAL NOTIFICATION
Reference number: 743700JJO2NU8LBS1592_20200830183117_2
____________________________________________
Transaction date: 2020-08-29
Venue not applicable
Instrument type: SHARE
ISIN: FI4000330972
Nature of the transaction: EXERCISE OF A STOCK OPTION
(X) Linked to stock option programme
Transaction details
(1): Volume: 10,000 Unit price: 1.1 EUR
Aggregated transactions
(1): Volume: 10,000 Volume weighted average price: 1.1 EUR
For further information, please contact:
Peter Hänninen, General Counsel
peter.hanninen@nanoform.com / +358 50 353 0408
For investor relations queries, please contact:
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com / +46 7686 650 11
Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 562 1806
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce attrition in clinical trials and enhance their molecules’ formulation performance through its nanoforming services. The Company’s patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) technology produces nanoformed API particles as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and by improving their bioavailability. Nanoform’s unique technology provides novel opportunities in many value-enhancing drug delivery applications. Nanoform’s share is listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS)
For more information please visit http://www.nanoform.com